CRIS Current Research Information System

MALAGOLA, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.102
EU - Europa 1.558
AS - Asia 717
AF - Africa 124
SA - Sud America 5
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
Totale 4.510
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.099
GB - Regno Unito 481
SE - Svezia 298
CN - Cina 257
DE - Germania 196
IT - Italia 192
SG - Singapore 187
VN - Vietnam 154
UA - Ucraina 72
IE - Irlanda 70
IN - India 66
FR - Francia 60
RU - Federazione Russa 58
TG - Togo 52
ZA - Sudafrica 36
EE - Estonia 31
CH - Svizzera 24
CI - Costa d'Avorio 20
BG - Bulgaria 17
FI - Finlandia 17
BE - Belgio 16
JO - Giordania 13
IR - Iran 11
NG - Nigeria 8
JP - Giappone 7
SC - Seychelles 7
LB - Libano 5
HK - Hong Kong 4
BR - Brasile 3
ES - Italia 3
EU - Europa 3
GR - Grecia 3
ID - Indonesia 3
NL - Olanda 3
PT - Portogallo 3
RO - Romania 3
TR - Turchia 3
CA - Canada 2
NO - Norvegia 2
PL - Polonia 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AR - Argentina 1
BA - Bosnia-Erzegovina 1
CL - Cile 1
CZ - Repubblica Ceca 1
HU - Ungheria 1
KE - Kenya 1
KG - Kirghizistan 1
LU - Lussemburgo 1
MK - Macedonia 1
MX - Messico 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 4.510
Salva come PNG Salva come JPEG
Città #
Southend 429
Fairfield 267
Chandler 201
Ashburn 174
Singapore 170
Woodbridge 155
Dong Ket 154
Wilmington 121
Seattle 120
Houston 119
Ann Arbor 113
Santa Clara 98
Cambridge 91
Princeton 87
Dublin 69
Boardman 58
Lomé 52
Nanjing 45
Jacksonville 42
Westminster 39
Padova 37
New York 36
Turin 31
Berlin 28
Beijing 23
Bologna 23
Bern 22
Saint Petersburg 22
Shenyang 21
Abidjan 20
Bremen 17
Florence 17
Helsinki 17
Sofia 17
Hebei 15
Amman 13
Brussels 13
Changsha 13
Jinan 11
Jiaxing 10
London 10
Milan 10
Medford 9
Nanchang 9
San Diego 9
Abeokuta 8
Guangzhou 7
Haikou 7
Mülheim 7
Norwalk 7
Verona 7
Des Moines 6
Mahé 6
Rome 6
Tokyo 6
Olalla 5
Redmond 5
Tianjin 5
Zhengzhou 5
Bühl 4
Chengdu 4
Farra d'Isonzo 4
Leawood 4
Ningbo 4
Phoenix 4
Shanghai 4
Taizhou 4
Wuhan 4
Zanjan 4
Ancona 3
Dongguan 3
Falkenstein 3
Falls Church 3
Fuzhou 3
Hangzhou 3
Hefei 3
Jakarta 3
Louvain 3
Mountain View 3
Muizenberg 3
Paris 3
Plauen 3
Redwood City 3
Riva 3
Shijiazhuang 3
Taiyuan 3
Washington 3
Afragola 2
Andover 2
Anyang 2
Bergen 2
Brescia 2
Castel Guelfo di Bologna 2
Central District 2
Chongqing 2
Costa Mesa 2
Foshan 2
Frankfurt am Main 2
Grafing 2
Hong Kong 2
Totale 3.264
Salva come PNG Salva come JPEG
Nome #
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 166
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. 164
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas 163
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 162
No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response? 158
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 153
Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. 139
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts 134
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 130
Leukemia and multi-drug resistance: too many mechanisms of drug resistance or too many doctors resistant? 127
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 126
Prompt resolution of nasal aspergillosis with intranasal instillation of liposomal amphotericin-B (amBisome) and granulocyte transfusions 122
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 122
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. 122
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 122
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 120
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 120
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia 116
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? 115
Consolidation therapy for adult acute myeloid leukemia: A systematic analysis according to evidence based medicine 114
Resolving the diagnostic dilemma of T-cell clonal expansion after hematopoietic stem cell transplantation in T-cell lymphoma patients by TCR-gamma next generation sequencing 110
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 108
Bcr-Abl kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the 2nd-generation TKI era 107
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 104
Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives 104
Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study. 102
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients 102
Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs) 100
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin 100
Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely. 96
Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation. 96
Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells) 94
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 91
Soft tissue and skeletal involvement in FIP1L1-PDGFR-A positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission 84
INTERMITTENT IMATINIB (INTERIM) TREATMENT IN PH+-CML ELDERLY PATIENTS IN STABLE COMPLETE CYTOGENETIC RESPONSE 82
The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. 76
Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome. 75
Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly 71
Molecular monitoring of acute myeloid leukemia associated with inv(16): Threshold of CBFβ/MYH11 transcript copy number above which relapse occurs and below which continuous complete remission is likely (multiple letters) [8] 55
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP 52
PROSPECTIVE PHASE II STUDY ON LOW-DOSE 5-AZACYTIDINE FOR TREATMENT OF SYMPTOMATIC PATIENTS WITH LOW/INT-1 RISK MYELODISPLASIA 33
Two more inv(16) acute myeloid leukemia cases with infrequent CBFβ-MYH11 fusion transcript: Clinical and molecular findings [4] 32
Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC 20
BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study 19
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study 12
Totale 4.620
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.099
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.099
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020646 0 0 0 0 0 0 148 150 161 87 39 61
2020/2021596 112 46 10 25 11 24 8 38 49 32 29 212
2021/2022744 47 16 64 99 71 50 13 45 32 59 138 110
2022/2023954 113 149 39 125 57 67 29 53 162 14 109 37
2023/2024262 17 39 13 30 15 69 12 29 5 16 9 8
2024/2025479 19 114 69 51 191 34 1 0 0 0 0 0
Totale 4.620